Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Hodgkin Disease 9Neoplasms 3Melanoma 3Uveal Melanoma 1Melanoma, Cutaneous Malignant 1Lung Neoplasms 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Kidney Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Melanoma 1

Interventions

cabozantinib 5Nivolumab 4Ipilimumab 4Axitinib 4pembrolizumab 3Blood Specimen Collection 3zimberelimab 2atezolizumab 2Surveys and Questionnaires 2Sunitinib 2Irinotecan 2temsirolimus 1spartalizumab 1salicylhydroxamic acid 1palbociclib 1orellanine 1olaparib 1liposomal doxorubicin 1lenvatinib 1gallium Ga 68 dotatate 1fludarabine 1brodalumab 1belzutifan 1aldesleukin 1adagrasib 1Vincristine 1Temozolomide 1Taxes 1Selenomethionine 1Ropivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Dacarbazine × 90 days × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡